Nataniel H. Lester-Coll, M.D., was appointed Division Chief of Radiation Oncology at University of Vermont Larner College of Medicine and chair of the Department of Radiation Oncology at UVM Health Network, effective July 15.

UVM Cancer Center members Frances Carr, Ph.D., professor of pharmacology, and Seth Frietze, Ph.D., associate professor of biochemistry, have received an Impact Award from the Department of Defense that will allow them to continue their foundational and translational research investigating novel therapeutic strategies for thyroid cancer, the most common endocrine cancer worldwide.

Using a novel therapy discovered in the Cunniff Lab at the University of Vermont Cancer Center, RS Oncology, a privately held biopharmaceutical company focusing on novel treatments for rare and aggressive cancers, presented positive results from its Phase 1 study in patients with Malignant Pleural Mesothelioma (MPM) with Malignant Pleural Effusion (MPE) or MPE associated with other solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

(JUNE 18, 2024) James Gerson, M.D., assistant professor of medicine, spoke with WCAX-TV about a new treatment for blood cancer launched last year that appears to be saving lives.

The Vermont Lake Monsters is teaming up with the UVM Cancer Center for a game of hope, connection and cancer awareness.

(MAY 20, 2024) Randall Holcombe, M.D., M.B.A., director of the UVM Cancer Center, spoke with WCAX-TV about the more than 100 clinical trials the Cancer Center is currently running.

(APRIL 17, 2024) Randall Holcombe, M.D., M.B.A., director of the University of Vermont Cancer Center, discussed colorectal cancer in a Vermont Public interview.